Ondansetron + Aprepitant
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hematologic Diseases
Conditions
Hematologic Diseases, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia
Trial Timeline
Nov 1, 2009 → May 1, 2015
NCT ID
NCT00954941About Ondansetron + Aprepitant
Ondansetron + Aprepitant is a phase 2 stage product being developed by Merck for Hematologic Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT00954941. Target conditions include Hematologic Diseases, Acute Myelogenous Leukemia, Myelodysplastic Syndrome.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00954941 | Phase 2 | Completed |
Competing Products
20 competing products in Hematologic Diseases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| 120 mg LY2784544 | Eli Lilly | Phase 2 | 52 |
| RLYB116 for Injection | Rallybio | Phase 1 | 25 |
| DS3790a + Combination drug + Combination drug | Daiichi Sankyo | Phase 1/2 | 41 |
| Isavuconazole | Astellas Pharma | Phase 2 | 52 |
| isavuconazonium sulfate - intravenous + isavuconazonium sulfate - oral | Astellas Pharma | Phase 1 | 33 |
| DSP-5336 + [14C]-DSP-5336 | Sumitomo Pharma | Phase 1 | 33 |
| BBI608 + Dexamethasone + Bortezomib + Imatinib + Ibrutinib | Sumitomo Pharma | Phase 1 | 33 |
| Venetoclax + ethinyl estradiol/levonorgestrel | AbbVie | Phase 1 | 33 |
| ABT-888 + Temozolomide | AbbVie | Phase 1 | 33 |
| ABBV-101 | AbbVie | Phase 1 | 33 |
| elotuzumab + lenalidomide + dexamethasone oral + dexamethasone injection | AbbVie | Phase 2 | 52 |
| Capivasertib + Rabeprazole | AstraZeneca | Phase 1 | 33 |
| AZD9829 + AZD9829 | AstraZeneca | Phase 1/2 | 41 |
| ridaforolimus | Merck | Phase 2 | 52 |
| Pembrolizumab/vibostolimab coformulation | Merck | Phase 2 | 52 |
| Nemtabrutinib | Merck | Phase 1 | 33 |
| Nemtabrutinib | Merck | Phase 2 | 52 |
| ARQ 621 | Merck | Phase 1 | 33 |
| Nemtabrutinib | Merck | Phase 1 | 33 |
| Pelabresib | Novartis | Phase 3 | 77 |